Revisiting Injectable Estrogen Dosing Recommendations for Gender-Affirming Hormone Therapy.
Publication
, Journal Article
Rothman, MS; Hamnvik, O-PR; Davidge-Pitts, C; Safer, JD; Ariel, D; Tangpricha, V; Abramowitz, J; Soe, K; Sarvaideo, J; Kelley, C; Irwig, MS ...
Published in: Transgend Health
December 2024
Injectable estrogens are options for gender-affirming hormone therapy per guidelines, which suggest intramuscular dosages of 5-30 mg every 2 weeks or 2-10 mg weekly with estradiol cypionate or valerate interchangeably. Data among transgender and gender-diverse patients are limited due to local unavailability and concerns around laboratory assay variability and estradiol (E2) level fluctuation. We note a concerning trend where patients are prescribed high-dose injections based on the guidelines leading to serum E2 levels well above the range recommended in the same guidelines. Our review indicates that 5 mg weekly or lower should be prescribed when initiating injectable estrogens to avoid supraphysiologic E2 levels.
Duke Scholars
Published In
Transgend Health
DOI
ISSN
2688-4887
Publication Date
December 2024
Volume
9
Issue
6
Start / End Page
463 / 465
Location
United States
Related Subject Headings
- 4206 Public health
- 4203 Health services and systems
Citation
APA
Chicago
ICMJE
MLA
NLM
Rothman, M. S., Hamnvik, O.-P., Davidge-Pitts, C., Safer, J. D., Ariel, D., Tangpricha, V., … Iwamoto, S. J. (2024). Revisiting Injectable Estrogen Dosing Recommendations for Gender-Affirming Hormone Therapy. Transgend Health, 9(6), 463–465. https://doi.org/10.1089/trgh.2023.0209
Rothman, Micol S., Ole-Petter R. Hamnvik, Caroline Davidge-Pitts, Joshua D. Safer, Danit Ariel, Vin Tangpricha, Jessica Abramowitz, et al. “Revisiting Injectable Estrogen Dosing Recommendations for Gender-Affirming Hormone Therapy.” Transgend Health 9, no. 6 (December 2024): 463–65. https://doi.org/10.1089/trgh.2023.0209.
Rothman MS, Hamnvik O-PR, Davidge-Pitts C, Safer JD, Ariel D, Tangpricha V, et al. Revisiting Injectable Estrogen Dosing Recommendations for Gender-Affirming Hormone Therapy. Transgend Health. 2024 Dec;9(6):463–5.
Rothman, Micol S., et al. “Revisiting Injectable Estrogen Dosing Recommendations for Gender-Affirming Hormone Therapy.” Transgend Health, vol. 9, no. 6, Dec. 2024, pp. 463–65. Pubmed, doi:10.1089/trgh.2023.0209.
Rothman MS, Hamnvik O-PR, Davidge-Pitts C, Safer JD, Ariel D, Tangpricha V, Abramowitz J, Soe K, Sarvaideo J, Kelley C, Irwig MS, Iwamoto SJ. Revisiting Injectable Estrogen Dosing Recommendations for Gender-Affirming Hormone Therapy. Transgend Health. 2024 Dec;9(6):463–465.
Published In
Transgend Health
DOI
ISSN
2688-4887
Publication Date
December 2024
Volume
9
Issue
6
Start / End Page
463 / 465
Location
United States
Related Subject Headings
- 4206 Public health
- 4203 Health services and systems